Eli Lilly and Company (NYSE:LLY) Shares Down 1.5% After Insider Selling

Shares of Eli Lilly and Company (NYSE:LLY) traded down 1.5% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $1,209.53 and last traded at $1,212.9590. Approximately 2,087,326 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 3,132,333 shares. The stock had previously closed at $1,231.94.

Specifically, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Set New Price Targets

Several research analysts recently commented on LLY shares. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Guggenheim raised their target price on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Barclays increased their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,292.18.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. This is the pill’s first regulatory approval outside the United States and gives Lilly access to a major European market. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: The approval expands Lilly’s obesity portfolio beyond injectable medicines and could improve patient convenience and market adoption. Foundayo will initially be available through private prescriptions, while potential access through Britain’s National Health Service depends on a cost-effectiveness review. Lilly Takes Its Weight-Loss Pill Battle Overseas
• Positive Sentiment: Investor sentiment remains supported by Lilly’s strong recent results: quarterly revenue increased 47.7% year over year to $22.97 billion, while earnings per share of $8.38 exceeded the $6.40 consensus estimate. Management raised fiscal 2026 EPS guidance to $35.50–$36.50, marking another outlook increase. Eli Lilly Beat Big and Raised Guidance
• Neutral Sentiment: Analysts have lifted some valuation targets, with one updated fair-value estimate rising to $1,297.31. However, the stock is trading near its 52-week high and at roughly 41 times earnings, leaving less room for disappointment. Eli Lilly Fair Value Bump
• Negative Sentiment: Erste Group Bank lowered its fiscal 2026 EPS estimate to $34.93 from $35.34. Although the revised forecast remains close to Lilly’s guidance, the cut contrasts with the broader bullish outlook. Eli Lilly analyst estimate
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares for approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The scheduled nature of the transaction makes it a limited bearish signal, but it may add some selling pressure. SEC Form 4 Filing

Eli Lilly and Company Stock Performance

The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a 50-day moving average of $1,162.38 and a 200-day moving average of $1,048.95. The stock has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 40.70, a P/E/G ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 36.77 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 23.22%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC increased its stake in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after purchasing an additional 7,338 shares in the last quarter. Iams Wealth Management LLC purchased a new position in Eli Lilly and Company in the 4th quarter valued at about $754,000. Amundi lifted its stake in Eli Lilly and Company by 9.9% in the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after buying an additional 454,549 shares in the last quarter. May Hill Capital LLC boosted its holdings in Eli Lilly and Company by 131.6% in the 4th quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock worth $3,408,000 after buying an additional 1,801 shares during the last quarter. Finally, Caisse Des Depots ET Consignations boosted its holdings in Eli Lilly and Company by 17.3% in the 4th quarter. Caisse Des Depots ET Consignations now owns 10,834 shares of the company’s stock worth $11,643,000 after buying an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.